New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
09:05 EDTTRV, DD, VZ, JNJ, RIMM, NUS, CAT, CLSNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Travelers (TRV), up 3.5%... DuPont (DD), up 0.9%... ALSO HIGHER: Research In Motion (RIMM), up 7.1% after CEO reportedly says may license new BB10 operating system to other companies, upgrade to Outperform at Scotia Capital... Celsion (CLSN), up 11.4% after entering technology development agreement... DOWN AFTER EARNINGS: Verizon (VZ), down 0.9%... Johnson & Johnson (JNJ), down 0.9%... ALSO LOWER: Nu Skin (NUS), down 3.2% after NY Post says Dan Loeb's Third Point took "sizable" short position... Caterpillar (CAT), down 1.8% after announcing plans for $580M Q4 charge for accounting misconduct at unit.
News For TRV;DD;VZ;JNJ;RIMM;NUS;CAT;CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
07:40 EDTVZVerizon reports Q3 retail postpaid ARPA up 3.5% to $161.24
Subscribe for More Information
07:36 EDTVZVerizon backs FY14 target of 4% consolidated top-line growth
FY14 revenue consensus $126.08B. For the full year, results for consolidated adjusted and wireless segment EBITDA service margin will be dependent on Q4 volumes and installment take rates. Wireline segment EBITDA margin remains on track to expand on a full-year basis, Verizon said.
07:34 EDTVZVerizon sees FY14 capital spending near $17B
Subscribe for More Information
07:33 EDTVZVerizon CEO says seeing continued, healthy demand for wireless, broadband
Verizon Communications Chairman and CEO Lowell McAdam said: "We have great confidence heading into the fourth quarter, as Verizon continues to deliver consistently strong operating and financial results. We see continued, healthy customer demand for wireless and broadband services, and we are encouraged by the growth we are starting to see in the areas of video delivery and machine-to-machine. Our cash generation remains strong, and last month we were pleased to announce board approval of a quarterly dividend increase for the eighth consecutive year."
07:32 EDTVZVerizon reports Q3 EPS 89c, consensus 90c
Subscribe for More Information
06:59 EDTTRVTravelers reports Q3 net written premiums up 6% to $6.03B
Total capital returned to shareholders of $937 million in the quarter, including $751 million in share repurchases. Year-to-date total capital returned to shareholders of $2.885 billion. Increases in book value per share of 9% to $76.42 and adjusted book value per share of 6% to $70.64 from year-end 2013.
06:58 EDTTRVTravelers reports Q3 EPS $2.61, consensus $2.27
Subscribe for More Information
October 20, 2014
15:36 EDTTRV, VZNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTVZVerizon technical commentary before earnings
Subscribe for More Information
13:53 EDTVZEarnings Preview: Verizon sentiment mixed ahead of Q3 report
Subscribe for More Information
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
11:13 EDTNUSNu Skin volatility elevated
Nu Skin October weekly call option implied volatility is at 95, November is at 73, December is at 72; compared to its 26-week average of 48 according to Track Data, suggesting decreasing price movement.
08:30 EDTNUSNu Skin initiated with a Buy at Pivotal Research
Target $75.
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:17 EDTVZVerizon weekly volatility elevated into Q3 and outlook
Verizon October weekly call option implied volatility is at 25, November and January is at 16; compared to its 26-week average of 15 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 21.
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use